Effects of levetiracetam monotherapy on the cognitive function of epilepsy patients

Eur Neurol. 2013;70(1-2):88-94. doi: 10.1159/000347230. Epub 2013 Jul 2.

Abstract

Aims: To estimate the effect of levetiracetam (LEV) on cognitive function and mood status in newly diagnosed epilepsy patients.

Methods: Fifty-five drug-naïve epilepsy patients (M:F ratio = 31:24; mean age = 30.9 years) were included. All patients underwent two neuropsychological (NP) tests, one before receiving LEV and then another 12.9 ± 5.0 months after starting LEV monotherapy. We evaluated general cognitive function, verbal/visual attention and memory, linguistic and visuospatial functions, frontal lobe function, and mood status. Repeated-measures regression and generalized estimating equation models were applied to assess the effects of all the confounding variables such as seizure control, average LEV dose, duration of epilepsy, inter-test interval, and subtype of epilepsy syndrome.

Results: LEV monotherapy over 1 year revealed significant improvements in the following domains of NP tests with the correction of possible confounding variables: verbal and visual attention, psychomotor speed, mental flexibility, executive function, verbal fluency and word generation. No NP domains showed any significant decrease.

Conclusion: Our study suggested that LEV monotherapy had no harmful effect on cognitive function in drug-naïve patients with epilepsy.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Anticonvulsants / therapeutic use*
  • Child
  • Cognition / drug effects*
  • Epilepsy / drug therapy*
  • Female
  • Humans
  • Levetiracetam
  • Male
  • Middle Aged
  • Neuropsychological Tests
  • Piracetam / analogs & derivatives*
  • Piracetam / therapeutic use
  • Young Adult

Substances

  • Anticonvulsants
  • Levetiracetam
  • Piracetam